Arabska Mathilde, Girardin Marie-Laure, Long Laurence, Grillon Antoine, Zaloszyc Ariane
Service de pédiatrie, centre hospitalier Sainte-Catherine, 19, Côte de Saverne, 67700 Saverne, France.
Service de réanimation pédiatrique, hôpital de Hautepierre, CHU de Strasbourg, université de Strasbourg, 1, avenue Molière, 67000 Strasbourg, France.
Nephrol Ther. 2022 Apr;18(2):129-135. doi: 10.1016/j.nephro.2021.11.003. Epub 2022 Mar 5.
Febrile urinary tract infection (UTI) is a common health issue in pediatrics that can lead to serious infectious and renal complications, it requires early diagnosis and a targeted use of antibiotics. The aim of our study was to describe local bacterial agents causing febrile UTIs and their resistance patterns and confront the results with currently used empirical antibacterial therapy in pediatrics emergency departments in Strasbourg and Saverne.
We used billing codes (international classification of diseases) to identify all inpatients treated for febrile UTIs in two French pediatric emergency departments between January 2019 and December 2020. Microbial results of urine cultures were retrieved from the laboratory information system.
Among 214 microbial results from 208 patients, the distribution of uropathogens was 82% Escherichia coli, with extended-spectrum beta-lactamase in 2.8%, 7% Enterococcus faecalis, 5% Klebsiella, 2% Proteus mirabilis. E. coli was resistant respectively to amoxicillin, amoxicillin/clavulanic acid and cotrimoxazol in 43, 33 and 14% of samples. A third-generation cephalosporin administered intravenously was mainly used (98%) as empirical treatment. Less than 2% of patients were treated with oral cephalosporin from the start.
We present the spectrum of uropathogens and susceptibility test results in pediatric UTIs as well as the susceptibility pattern of E. coli, a local treatment protocol was designed based on our results in conformity with national guidelines.
发热性尿路感染(UTI)是儿科常见的健康问题,可导致严重的感染和肾脏并发症,需要早期诊断并针对性使用抗生素。我们研究的目的是描述引起发热性UTI的当地细菌病原体及其耐药模式,并将结果与斯特拉斯堡和萨韦尔讷儿科急诊科目前使用的经验性抗菌治疗进行对比。
我们使用计费代码(国际疾病分类)来识别2019年1月至2020年12月期间在两个法国儿科急诊科接受发热性UTI治疗的所有住院患者。从实验室信息系统中获取尿培养的微生物结果。
在208例患者的214份微生物结果中,尿路病原体的分布为82%为大肠杆菌,其中2.8%产超广谱β-内酰胺酶,7%为粪肠球菌,5%为克雷伯菌属,2%为奇异变形杆菌。大肠杆菌对阿莫西林、阿莫西林/克拉维酸和复方新诺明的耐药率分别为43%、33%和14%。静脉注射第三代头孢菌素主要用作经验性治疗(98%)。从一开始就接受口服头孢菌素治疗的患者不到2%。
我们展示了儿科UTI中尿路病原体的谱图和药敏试验结果以及大肠杆菌的药敏模式,根据我们的结果并符合国家指南设计了当地的治疗方案。